

# Hyperplasia

Adaptations of cellular growth and differentiation

**Dr Abu Suraih Sakhri**


MBBS, MD (Pathology)

[www.abusuraihsakhri.com](http://www.abusuraihsakhri.com)

## Learning outcomes

- Define hyperplasia in terms of cell number and proliferative capacity.
- Distinguish physiologic hormonal and compensatory hyperplasia from pathologic responses.
- Explain the major breast, liver, marrow, endometrial, prostatic, and viral examples.
- Relate regulated proliferation to reversibility and potential cancer risk.


# Cellular adaptations respond to a stimulus




Hyperplasia describes how a tissue grows: Through more cells.

# Hyperplasia increases cell number

Before stimulus



After stimulus



Within a comparable field, the number of cells increases

*Schematic — conceptual comparison; Not a histologic specimen*

# Hyperplasia and hypertrophy are distinct

| Feature                 | Hyperplasia                             | Hypertrophy                             |
|-------------------------|-----------------------------------------|-----------------------------------------|
| Primary change          | Increased cell number                   | Increased cell size                     |
| Requires cell division? | Yes — cells must be capable of dividing | No — cells can enlarge without dividing |
| Can coexist?            | Yes                                     | Yes                                     |
| Source example          | Breast glandular epithelium             | Breast epithelial cell enlargement      |

An enlarged organ does not identify which cellular adaptation produced the growth.


## **Proliferative capacity is a prerequisite**

- Hyperplasia requires tissue cells with the ability to divide.
- The same stimulus may produce different outcomes in different tissues.
- Tissues with minimal division may increase cell mass predominantly by hypertrophy.
- Interpret the adaptive response in relation to the cells involved.


Cell type limits the possible growth response.

# Cell number versus cell size: Visual test

Same population of cells



Enlarged individual cells



Cell number remains similar; Individual cells enlarge

*Schematic — conceptual comparison; Not a histologic specimen*

## Hyperplasia and hypertrophy often coexist

- Both responses may be triggered by the same external stimulus.
- One tissue may contain more cells and larger cells simultaneously.
- Breast glandular epithelium during normal hormonal adaptation illustrates this combination.
- The relative contribution varies by tissue and stimulus.

Do not force a single-mechanism label on mixed adaptive growth.

# Two broad categories of hyperplasia

## Physiologic


- Appropriate hormonal or growth-factor action
- Increased functional capacity
- Compensation for damage or resection

## Pathologic

- Excessive or inappropriate hormonal / growth-factor action
- Abnormal enlargement of responding cell populations
- May stabilize or regress when the stimulus is removed

“Pathologic” identifies an abnormal stimulus-response setting, not necessarily cancer.

# The organizing questions for any example




Identify stimulus → responsive cell population → functional consequence.

## What is—and is not—implied by hyperplasia

- The term describes a quantitative change in the cellular population.
- Its causes and consequences depend on the specific organ and stimulus.
- Hyperplasia can occur during normal development or tissue compensation.
- A diagnosis of hyperplasia alone does not establish malignancy.

A morphologic response must be interpreted in its biologic context.

## A brief mechanism bridge



More detailed signaling and stem-cell biology belong to the next Robbins topic.

# Physiologic hyperplasia: Three exemplars

## Breast

- Hormonal stimulation
- Increased glandular epithelial cells
- Often combined with hypertrophy

## Liver

- Partial tissue loss
- Proliferation of remaining cells
- Recovery toward original size

## Bone marrow

- Deficiency of mature blood cells
- Feedback growth-factor signaling
- More blood-cell progenitors


Physiologic hyperplasia can be hormonal or compensatory.

# Hormonal hyperplasia of the breast

- Female breast glandular epithelium is a hormone-responsive tissue.
- At puberty, glandular epithelial cells proliferate.
- During pregnancy, glandular epithelial proliferation is again prominent.
- The response supports enlargement of the hormone-sensitive organ.


The cells undergoing hyperplasia are specified: Glandular epithelial cells.

# Puberty: A physiologic proliferative response



This is a normal developmental stimulus, not an autonomous lesion.

# Pregnancy: Hormonal adaptation of the breast



One stimulus can lead to hyperplasia plus hypertrophy.

# The breast illustrates mixed growth mechanisms

## Cell-number change

- Additional glandular epithelial cells
- Requires competent proliferation
- Defines hyperplasia

## Cell-size change

- Enlargement of epithelial cells
- Can occur concurrently
- Defines hypertrophy

Describe both alterations where the source documents both.

# Case: Glandular breast growth in pregnancy

## Clinical or experimental scenario

During pregnancy, the glandular epithelium of the breast expands and individual epithelial cells enlarge.

## Reason through

- Which component is hyperplasia?
- Which component is hypertrophy?
- Why is the overall response physiologic?

# Reasoning: Pregnancy-related breast growth

## Explanation


- More glandular epithelial cells = hyperplasia.
- Larger glandular epithelial cells = hypertrophy.
- The stimulus arises in a normal hormonal setting to increase organ capacity.

The process classification depends on both mechanism and context.

# **Liver regeneration is compensatory hyperplasia**

- Partial removal of the liver reduces the remaining organ mass.
- Residual cells can proliferate to replace lost tissue capacity.
- The remaining liver can grow back toward its original size.
- This is a classic model of compensatory hyperplasia.

# Partial hepatectomy: The adaptive sequence




Compensation is driven by cell proliferation, not replacement of the removed lobe as a discrete new lobe.

## What the donor-liver example demonstrates

- An organ can recover lost mass by proliferation of surviving cells.
- The stimulus follows removal of part of the organ, not an abnormal endocrine excess.
- Growth is an adaptive response to diminished tissue capacity.
- Partial hepatectomy models have informed understanding of regeneration.

Tissue loss can trigger a regulated proliferative program.

# Liver-cell proliferation: Source-level mechanism



The neighboring topic expands this mechanistic sequence.

# How new liver cells may arise

## Surviving mature cells

- Residual hepatocytes may proliferate
- Growth factors stimulate replication
- Major explanation in partial hepatectomy

## Tissue stem cells

- May contribute when hepatocyte division is impaired
- Described for some hepatitic injury settings
- A conditional alternative, not the default for every resection

Regeneration need not always recruit the same cellular source.

## **Regeneration is not unrestricted growth**

- Hyperplasia answers a specific tissue-loss stimulus.
- The organ-size response is described as recovery toward the original size.
- No autonomous neoplastic process is required to explain the response.
- An adaptive increase in cell number can be substantial without being malignant.

# Case: Living-donor liver remnant

## Clinical or experimental scenario

After donation of part of a liver, the remaining hepatic tissue enlarges in the course of regeneration.

## Reason through

- What adaptive process accounts for additional liver cells?
- What stimulus initiates this response?
- Which possible cell populations can supply new cells?

# Reasoning: Liver remnant

## Explanation


- Compensatory hyperplasia follows loss of tissue mass.
- Growth-factor signaling promotes proliferation of surviving hepatocytes.
- When mature-cell proliferative capacity is compromised, tissue stem cells may contribute.

Identify the compensatory trigger before describing the mechanism.

## **Bone marrow has substantial adaptive capacity**


- Production of mature blood cells is linked to demand.
- Deficiency of mature circulating blood cells triggers compensatory responses.
- Hematopoietic progenitor populations can expand rapidly.
- This capacity is a physiologic example of hyperplasia.

# Blood loss can stimulate marrow hyperplasia



The expanded marrow precursor pool helps restore red-cell production.

# Hemolysis can stimulate the same response




Distinct causes of red-cell deficiency may converge on marrow hyperplasia.

## **Erythropoietin links demand to proliferation**

- Erythropoietin is a growth factor in erythroid feedback.
- Feedback loops are activated by bleeding or hemolysis.
- Growth of red-cell progenitors increases the capacity for erythropoiesis.
- The biologic target is the precursor population, not the mature circulating erythrocyte.

# The feedback logic of erythroid hyperplasia



Compensatory marrow growth responds to a deficiency in the mature cell compartment.

## A source-reported quantitative example

- Red-cell production can increase as much as eightfold.
- This occurs when erythropoietin-related feedback stimulates erythroid progenitors.
- The statement illustrates substantial reserve in hematopoietic responses.
- It is not presented as the response magnitude in every patient.

“As much as” identifies a potential capacity, not an expected fixed response.

# Hemorrhage and hemolysis: Same marrow principle

| Feature             | Acute blood loss                     | Premature red-cell breakdown         |
|---------------------|--------------------------------------|--------------------------------------|
| Primary problem     | Mature red cells are lost externally | Mature red cells are destroyed early |
| Compensation        | Erythropoietin feedback              | Erythropoietin feedback              |
| Response population | Erythroid progenitors                | Erythroid progenitors                |
| Adaptation          | Marrow hyperplasia                   | Marrow hyperplasia                   |

Classify by the proliferating compartment rather than by the trigger alone.

# Case: Increased marrow erythropoiesis

## Clinical or experimental scenario

Following acute hemorrhage, the hematopoietic tissue expands its erythroid progenitor population.

## Reason through

- Which tissue exhibits hyperplasia?
- Which population increases in number?
- Why is this a compensatory rather than an autonomous response?

# Reasoning: Marrow after hemorrhage

## Explanation

- The adaptive tissue is hematopoietic bone marrow.
- The expanding cells are red-cell progenitors.
- Feedback through erythropoietin links the proliferative response to red-cell deficiency.

Blood-cell deficits can be compensated by increased production at the precursor stage.

# Physiologic and pathologic growth signals

## Appropriate stimulus

- Normal hormonal demand
- Functional capacity requirement
- Loss of tissue or mature cells

## Excess or inappropriate stimulus

- Hormonal imbalance
- Abnormal action of growth signals
- Virally perturbed proliferation control


A shared proliferative mechanism can have different biologic meanings.

## **Pathologic hyperplasia still requires signals**

- Most pathologic examples reflect excessive or inappropriate hormonal or growth-factor action.
- Target cells retain the ability to proliferate in response.
- The increased cell number is abnormal in context.
- Abnormal proliferation need not be autonomous cancer growth.

Abnormal stimulation is not synonymous with malignant transformation.

# Hormonal imbalance can cause pathologic growth




The identity of the hormone and target tissue changes by organ.

## Why pathologic hyperplasia remains controlled

- The source distinguishes hyperplasia from cancerous, unrestrained growth.
- Removal of abnormal hormonal stimulation may permit regression.
- Alternatively, the hyperplastic lesion may stabilize.
- Reversibility is an important biologic distinction, not a universal treatment guarantee.

An abnormal cell population can remain dependent on an external stimulus.

# Removing a growth stimulus



The response to withdrawal helps distinguish stimulus dependence from autonomous growth.

## **Normal endometrium undergoes cyclic proliferation**

- After menstruation, endometrial proliferation increases rapidly.
- Pituitary hormones and ovarian estrogen support this response.
- The growth phase is regulated within the menstrual cycle.
- Normal regulation includes an eventual halt to proliferation.

# Normal endometrial proliferation has a brake




Estrogen-related proliferation is physiologic when appropriately regulated.

# Progesterone restrains endometrial proliferation

- The rising level of progesterone normally halts proliferation.
- This restraint about 10–14 days before the end of the menstrual period.
- A normal proliferative burst therefore does not continue unchecked.
- The estrogen–progesterone balance is central to this example.

Failure of restraint is a route to pathologic hyperplasia.

# Endometrial hyperplasia: The causal sequence



The target population is the endometrial glandular epithelium.

# Absolute versus relative estrogen excess

## Absolute increase

- An increase in estrogen amount can enhance proliferative drive
- Regulatory balance becomes abnormal

## Relative predominance

- Estrogen action may be excessive relative to progesterone restraint
- The relationship between signals matters


Hormonal balance—not merely one isolated absolute level—determines the proliferative context.

## Why the endometrial glands expand


- Estrogen stimulates endometrial glandular proliferation.
- Normal progesterone-associated restraint is insufficient or disrupted.
- Prolonged proliferative signaling increases the number of glandular cells.
- This is abnormal hormone-induced hyperplasia.

# Endometrial gland proliferation: Schematic

Regulated glandular growth



Hyperplastic glandular growth



Conceptual illustration: Increased glandular epithelial proliferation, not a diagnostic micrograph.


*Schematic — no histologic grading or diagnostic architecture is implied*

## **Clinical consequence: Abnormal uterine bleeding**

- Endometrial hyperplasia is a common cause of abnormal uterine bleeding.
- The proliferating glandular compartment is hormonally responsive.
- The clinical manifestation must be understood alongside hormonal context.
- The source does not supply a diagnostic algorithm or quantitative bleeding risk here.

A cell-growth mechanism can have a direct clinical expression.

## Endometrial case: Link stimulus to symptom



The chain is causal at source level; It is not a complete differential diagnosis for bleeding.

# Endometrial hyperplasia and cancer risk

- Hyperplasia itself is not synonymous with carcinoma.
- Increased cell division can provide opportunities for genetic aberrations.
- The source identifies endometrial hyperplasia as associated with increased cancer risk.
- This association should not be interpreted as inevitable malignant progression.

Risk elevation is not a diagnosis of malignancy.

# Case: Abnormal endometrial proliferation

## Clinical or experimental scenario

An abnormal estrogen–progesterone balance is followed by excessive proliferation of the endometrial glands and abnormal uterine bleeding.

## Reason through

- Which stimulus is abnormal?
- Which cells are increasing in number?
- Does the term “hyperplasia” alone diagnose cancer?

# Reasoning: Endometrial hyperplasia

## Explanation

- Estrogenic proliferative influence is excessive in absolute or relative terms.
- The expanding cell population is the endometrial glandular epithelium.
- This remains hyperplasia; Cancer risk may be elevated, but cancer is not established.


Separate causal mechanism, clinical manifestation, and malignant potential.

# **Benign prostatic hyperplasia is pathologic hyperplasia**

- The prostate is another hormone-responsive organ.
- Androgen stimulation as the relevant pathologic stimulus.
- The responding tissue increases its cellular population.
- The example illustrates a common abnormal hyperplastic response.

The source establishes hormonal causation here, not a complete clinical BPH model.

# Benign prostatic hyperplasia: Source-level model



Benign and pathologic are compatible terms: Abnormal response, not malignant cancer.

# Endometrium and prostate: What differs?

## Endometrium

- Hormonal balance: Estrogen versus progesterone
- Hyperplasia of endometrial glands
- Abnormal uterine bleeding is cited

## Prostate

- Hormonal influence: Androgens
- Benign prostatic hyperplasia is cited
- Detailed symptoms are outside this source section


The common principle is hormone-associated proliferation of responsive tissue.

## **Do not confuse benign hyperplasia with cancer**

- “Benign prostatic hyperplasia” names a nonmalignant hyperplastic condition.
- The source describes pathologic hyperplasia as controlled and often signal dependent.
- A label of pathologic hyperplasia does not by itself imply invasive neoplasia.
- Cancer-associated risk statements must be organ- and lesion-specific.

Avoid transferring the risk of one hyperplastic condition to another.

# From regulated proliferation to potential risk



This is a risk framework, not an automatic progression pathway.

# Hyperplasia versus cancer: Source-supported distinctions

| Question               | Hyperplasia                                   | Cancer                                     |
|------------------------|-----------------------------------------------|--------------------------------------------|
| Cell growth            | Increased cell number                         | Unrestrained proliferation is emphasized   |
| Dependence on stimulus | Often remains hormone/growth-factor dependent | May be driven by acquired genetic changes  |
| Reversal               | May regress or stabilize if signal removed    | No such general regression claim in source |
| Relationship           | Can be a risk setting                         | A distinct pathologic process              |

“Hyperplasia” and “cancer” name different biologic states.

## What can be inferred about cancer risk?


- The risk depends on the specific hyperplastic process.
- Robbins specifically links endometrial hyperplasia with increased endometrial cancer risk.
- It also notes that some papillomavirus-induced epithelial proliferations are precursors.
- The excerpt does not classify every hyperplasia as premalignant.

Retain the qualifiers “some” and “risk”; Avoid deterministic language.

## **Papillomaviruses can cause epithelial hyperplasia**

- Certain viral infections characteristically trigger hyperplasia.
- Papillomaviruses are the example identified in the text.
- They produce skin warts and several mucosal lesions.
- The lesions consist of masses of hyperplastic epithelium.

# Papillomavirus-induced proliferative response



Viral disturbance of cell-growth control is a distinct pathologic trigger.

# Site of viral hyperplasia

## Skin

- Papillomavirus-associated warts
- Accumulations of hyperplastic epithelium
- Evidence of a virus-associated proliferation response

## Mucosal epithelium

- Several mucosal lesions may occur
- Epithelial hyperplasia is described
- Some lesions are precursors to cancer

An etiologic stimulus may produce hyperplasia at more than one epithelial site.

## **Not all virally induced hyperplasias are equivalent**

- The source states that some viral proliferations can precede cancer.
- It does not say every cutaneous wart transforms.
- Different lesion types require their own diagnostic context.
- Maintain the distinction between epithelial overgrowth and malignant transformation.

Do not overinterpret a viral stimulus as proof of carcinoma.

# Three pathologic pathways to compare

## Endometrium

- Estrogen predominance
- Glandular proliferation
- Abnormal bleeding;  
Cancer risk noted

## Prostate

- Androgenic stimulation
- Benign hyperplasia
- Hormone-associated  
tissue expansion

## Papillomavirus

- Viral interference
- Epithelial hyperplasia
- Warts / mucosal lesions;  
Some precursors

Similar growth phenotype; Distinct stimuli and clinical implications.

## Physiologic examples: Trigger and response

| Example         | Initiating stimulus          | Responding population                                             |
|-----------------|------------------------------|-------------------------------------------------------------------|
| Breast growth   | Puberty / pregnancy hormones | Glandular epithelium                                              |
| Residual liver  | Partial removal of liver     | Surviving hepatocytes; possibly stem cells when capacity impaired |
| Marrow response | Bleeding or hemolysis        | Red-cell progenitors                                              |

The term “hyperplasia” applies to different cell populations across organs.

## Pathologic examples: Trigger and consequence

| Example        | Stimulus                             | Consequence emphasized in Robbins                       |
|----------------|--------------------------------------|---------------------------------------------------------|
| Endometrium    | Absolute/relative estrogen excess    | Excess glands; abnormal bleeding; increased cancer risk |
| Prostate       | Androgen stimulation                 | Benign prostatic hyperplasia                            |
| Papillomavirus | Viral perturbation of growth control | Warts / mucosal lesions; some are cancer precursors     |

The clinical and neoplastic implications cannot be generalized across examples.

## A practical way to classify tissue overgrowth

- First establish that cell number, rather than only cell size, has increased.
- Identify the proliferating population and its capacity to divide.
- Ask whether the signal is appropriate, compensatory, excessive, or virally perturbed.
- Then interpret local consequences and any specifically established cancer association.

Classification requires mechanism, context, and organ specificity.

## Application: Match the stimulus

### Clinical or experimental scenario

Consider three separate observations: Breast growth during pregnancy; Marrow erythroid expansion after hemolysis; Endometrial gland expansion under estrogen predominance.

### Reason through

- Which two observations are physiologic responses?
- Which is pathologic hyperplasia?
- Name the proliferating cell population in each.

## Application: Match the three examples

### Explanation

- Pregnancy-related breast glandular proliferation is physiologic hormonal hyperplasia.
- Hemolysis-related red-cell progenitor expansion is physiologic compensatory hyperplasia.
- Estrogen-predominant endometrial glandular expansion is pathologic hyperplasia.

The trigger and biologic context determine the classification.

# Application: Cancer-risk reasoning

## Clinical or experimental scenario

A student states: “Every hyperplastic lesion is a precursor of cancer because hyperplasia increases cell division.”

## Reason through

- Which part of the statement is supported?
- Which conclusion goes beyond the source?
- Which named examples carry a stated risk association?

# Application: Precise cancer-risk language

## Explanation

- Increased division can increase opportunities for genetic aberrations.
- Robbins does not state that every hyperplasia will progress to cancer.
- The excerpt specifically highlights endometrial hyperplasia and some viral epithelial proliferations.

Use probabilistic risk statements, never inevitable-progression claims.

## **Synthesis: Five defensible statements**

- Hyperplasia means more cells in a stimulated tissue.
- Cell division competence is necessary; Hypertrophy may coexist.
- Physiologic hyperplasia is hormonal or compensatory.
- Most pathologic forms involve excessive/inappropriate signals; Viral control interference is another example.
- Hyperplasia is distinct from cancer, although some processes elevate risk.

## Primary reference and scope

- Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th edition (2026).
- Chapter 2: Cell Injury, Cell Death, and Adaptations; “Hyperplasia,” printed pp. 53–54.
- Brief supporting mechanism explanation: “Mechanisms of Hyperplasia,” p. 54.
- Original diagrams are editable schematics, not histologic or clinical specimens.